Biocardia Valuation
| BCDA Stock | USD 1.27 0.02 1.60% |
Today, the firm appears to be undervalued. Biocardia shows a prevailing Real Value of $4.79 per share. The current price of the firm is $1.27. Our model approximates the value of Biocardia from analyzing the firm fundamentals such as Current Valuation of 8.83 M, shares owned by insiders of 26.66 %, and Return On Equity of -3.17 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Biocardia's price fluctuation is relatively risky at this time. Calculation of the real value of Biocardia is based on 3 months time horizon. Increasing Biocardia's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biocardia is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biocardia Stock. However, Biocardia's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.27 | Real 4.79 | Hype 1.28 | Naive 1.32 |
The real value of Biocardia Stock, also known as its intrinsic value, is the underlying worth of Biocardia Company, which is reflected in its stock price. It is based on Biocardia's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biocardia's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biocardia helps investors to forecast how Biocardia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biocardia more accurately as focusing exclusively on Biocardia's fundamentals will not take into account other important factors: Biocardia Total Value Analysis
Biocardia is currently forecasted to have valuation of 8.83 M with market capitalization of 13.48 M, debt of 951 K, and cash on hands of 8.61 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biocardia fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.83 M | 13.48 M | 951 K | 8.61 M |
Biocardia Investor Information
About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.42. Biocardia last dividend was issued on the 6th of June 2019. The entity had 1:15 split on the 30th of May 2024. Based on the key measurements obtained from Biocardia's financial statements, Biocardia is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Biocardia Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biocardia has an asset utilization ratio of 1.56 percent. This suggests that the Company is making $0.0156 for each dollar of assets. An increasing asset utilization means that Biocardia is more efficient with each dollar of assets it utilizes for everyday operations.Biocardia Ownership Allocation
The market capitalization of Biocardia is $13.48 Million. Biocardia retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Biocardia Profitability Analysis
The company reported the previous year's revenue of 58 K. Net Loss for the year was (7.95 M) with loss before overhead, payroll, taxes, and interest of (5.25 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biocardia's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biocardia and how it compares across the competition.
About Biocardia Valuation
The stock valuation mechanism determines Biocardia's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biocardia. We calculate exposure to Biocardia's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biocardia's related companies.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |